Categories
Credit Cards

Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is roughly 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The current opinion among eleven TipRanks analysts is actually for a modest Buy rating of shares in CVS Health, with an average price goal of $84.

The analysts price targets range from a high of $101 to a low of sixty one dolars.

In its newest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is $99.57 billion.

Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with four stars on a 0-5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management strategies. The retail or Long Term Care segment includes offering of prescribed drugs as well as assortment of general merchandise.

The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products and related services, which includes medical, pharmacy, dental, behavioural health, healthcare control abilities. The Corporate segment involves in providing management as well as administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *